Literature DB >> 19219416

[Relevance of ESBL-producing pathogens for clinical surgery: diagnostics, therapy, and prevention].

S Lehner1, B Grabein, P Pfaller, R Kopp.   

Abstract

BACKGROUND: Multiresistant, extended spectrum beta lactamase (ESBL)-producing pathogens are an increasing problem in daily clinical life. This paper summarizes the development of resistance as well as epidemiology, diagnostics, and treatment of ESBL-producing micro-organisms. We analyzed microbiological data collected at the Grosshadern Clinic in Germany between 1996 and 2007, in order to assess the importance of these micro-organisms to medical practice and surgical care units. PATIENTS AND METHODS: Pathogens were isolated from 28,894 patients with Escherichia coli and 10,903 with Klebsiella pneumoniae pathogens between 1996 and 2006 and tested for ESBL production. For the year 2007 we have analyzed the complete spectrum of ESBL-producing pathogens and their distribution to different departments of the clinic. The agar diffusion test with five cephalosporins and an automated detection system (BD Phoenix) were used for screening purposes. Positive results were verified with the E- and double-disc agar diffusion tests.
RESULTS: The most important pathogens isolated from patients were E. coli and K. pneumoniae. Analysis of ESBL-producing E. coli pathogens from 1996 to 2006 showed the prevalence increasing from 0% to 4.1%. For ESBL-producing K. pneumoniae, we also found a prevalence rising from 0.3% in 1996 to 6.6% in 2006. For the year 2007 a further increase in ESBL-producing pathogens was detected, reaching 182 cases, with 118 of ESBL-producing E. coli (5.7 %) and 39 of ESBL-producing K. pneumoniae (7.4%). Of these, 24 cases with E. coli and nine with K. pneumoniae were surgery patients (20% and 23%, respectively).
CONCLUSION: The results show an increasing prevalence of ESBL-producing pathogens in hospitalized patients and in surgical departments. The resulting rise in treatment costs and patient risk require thorough knowledge of risk factors, therapy, and preventive measures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19219416     DOI: 10.1007/s00104-008-1664-x

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  7 in total

1.  Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population.

Authors:  J A Rebuck; K M Olsen; P D Fey; A N Langnas; M E Rupp
Journal:  Clin Infect Dis       Date:  2000-11-10       Impact factor: 9.079

Review 2.  Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases.

Authors:  Michael A Pfaller; John Segreti
Journal:  Clin Infect Dis       Date:  2006-04-15       Impact factor: 9.079

Review 3.  Genetics of extended-spectrum beta-lactamases.

Authors:  G A Jacoby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

4.  Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital.

Authors:  Eileen M Graffunder; Karen E Preston; Ann M Evans; Richard A Venezia
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

Review 5.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 6.  Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum beta-lactamases.

Authors:  Andrea Endimiani; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2007-12       Impact factor: 3.119

7.  Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period.

Authors:  H Hanberger; L G Burman; O Cars; M Erlandsson; H Gill; L E Nilsson; D Nordlinder; S M Walther
Journal:  Acta Anaesthesiol Scand       Date:  2007-08       Impact factor: 2.105

  7 in total
  2 in total

1.  Isolation of Extended Spectrum β-lactamase (ESBL) Producing Bacteria from Urban Surface Waters in Malaysia.

Authors:  Shehani Tissera; Sui Mae Lee
Journal:  Malays J Med Sci       Date:  2013-05

2.  Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions.

Authors:  Christian Eckmann; M Dryden; P Montravers; R Kozlov; G Sganga
Journal:  Eur J Med Res       Date:  2011-03-28       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.